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ab
stract
PURPOSE Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with
malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efﬁcacy of
this treatment is uncertain. In this study, we aimed to determine the efﬁcacy of prophylactic radiotherapy in
reducing the incidence of chest wall metastases (CWM) after a procedure in MPM.
METHODS After undergoing a chest wall procedure, patients with MPM were randomly assigned to receive
prophylactic radiotherapy (within 42 days of the procedure) or no radiotherapy. Open thoracotomies, needle
biopsies, and indwelling pleural catheters were excluded. Prophylactic radiotherapy was delivered at a dose of
21 Gy in three fractions over three consecutive working days, using a single electron ﬁeld adapted to maximize
coverage of the tract from skin surface to pleura. The primary outcome was the incidence of CWM within
6 months from random assignment, assessed in the intention-to-treat population. Stratiﬁcation factors included
epithelioid histology and intention to give chemotherapy.
RESULTS Between July 30, 2012, and December 12, 2015, 375 patients were recruited from 54 centers and
randomly assigned to receive prophylactic radiotherapy (n = 186) or no prophylactic radiotherapy (n = 189).
Participants were well matched at baseline. No signiﬁcant difference was seen in the incidence of CWM at
6months between the prophylactic radiotherapy and no radiotherapy groups (no. [%]: 6 [3.2] v 10 [5.3], respectively;
odds ratio, 0.60; 95% CI, 0.17 to 1.86; P = .44). Skin toxicity was the most common radiotherapy-related adverse
event in the prophylactic radiotherapy group, with 96 patients (51.6%) receiving grade 1; 19 (10.2%), grade 2; and
1 (0.5%) grade 3 radiation dermatitis (Common Terminology Criteria for Adverse Events, version 4.0).
CONCLUSION There is no role for the routine use of prophylactic irradiation to chest wall procedure sites in
patients with MPM.
J Clin Oncol 37:1200-1208. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Malignant pleural mesothelioma (MPM) is almost
exclusively linked to asbestos exposure and has a la-
tency period of 12 to 50 or more years.1-3 Survival rates
are gradually improving but remain poor, with 2-year
survival ranging from 17% to 46%, according to
clinical stage, in the United States.4
The diagnosis and treatment of MPM usually involves an
invasive procedure at the chest wall, which can cause
tumor-cell seeding at the site of the procedure and result
in the development of a subcutaneous tumor. Studies
have reported that the incidence of chest wall metas-
tases (CWM) ranges from 2% to 50%.5-13
To minimize tumor seeding and prevent the devel-
opment of CWM, it has been widespread practice
for the last two decades to deliver prophylactic ra-
diotherapy to the site of the chest wall procedure,14,15
although the efﬁcacy of this approach is uncertain and
based on conﬂicting data from underpowered clinical
trials conducted before the era of chemotherapy.16-20
This has resulted in conﬂicting recommendations in
international guidelines and consensus that suitably
powered randomized trials are needed.21-24 In the
current trial, the aim was to determine whether pro-
phylactic radiotherapy after a chest wall procedure
reduces the incidence of CWM.
METHODS
Study Design
This multicenter, open-label, phase III, randomized
controlled trial recruited patients from 54 hospitals
across the United Kingdom. Participants gave written
informed consent and the study was performed
according to the Declaration of Helsinki and Good
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Clinical Practice Guidelines. The trial and subsequent
protocol amendments were approved by the Greater
Manchester West Ethics Committee of the UK National
Research Ethics Service (12/NW/0249). The full protocol
was published before the completion of trial follow-up.25
Participants
Eligible patients were aged 18 years or older; had a di-
agnosis of MPM conﬁrmed by a thoracic malignancy
multidisciplinary team; had inoperable disease or were
medically unsuitable for surgery; had an Eastern
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Randomly Assigned 
(N = 375)
Prophlyactic 
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(n = 186)
No radiotherapy
(n = 189)
Received 
chemotherapy 
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Received 
chemotherapy
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Included in intention-
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Included in intention-
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FIG 1. Trial proﬁle. CWM,
chest wall metastases.
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Cooperative Oncology Group performance status score of
0 to 2; had undergone a chest wall procedure, including
open surgical biopsy, video-assisted thoracoscopic surgery
biopsy, local anesthetic thoracoscopy, or insertion of
a chest drain; had a chest wall procedure scar visible at
time of random assignment; and were able to start pro-
phylactic radiotherapy within 42-days of the chest wall
procedure.
Patients were ineligible if they had an open thoracotomy
(the resulting large scar or tract would not be adequately
covered with the electron ﬁeld arrangement used) or had
undergone a needle biopsy (the resulting scar would not be
visible at the time of random assignment), had received
previous thoracic radiotherapy to the region of the chest
wall procedure site, were currently receiving chemother-
apy, or had an indwelling pleural catheter in situ at the
chest wall procedure site.
Randomization and Masking
Patients were randomly assigned on 1:1 to receive either
prophylactic radiotherapy or observation. A variant of an
adaptive, biased-coin randomization method was used
to favor balanced allocations in the four strata formed
from epithelioid histology (no/yes) and intention to give
chemotherapy (no/yes). Allocations were to the lower
recruiting arm within a stratum with probability 0.5 if the
imbalance was within a predeﬁned limit (3 for no intention
and 6 for intention to give chemotherapy) and 0.75 other-
wise. Randomization was undertaken centrally using
a bespoke randomization computer system. Patients and
clinicians were not masked to treatment allocation.
Procedures
A detailed account of the procedure is given in the pub-
lished full protocol.25 Patients randomly assigned to the
prophylactic radiotherapy group started prophylactic ra-
diotherapy within 42 days of the most recent chest wall
procedure. Radiotherapy was delivered using a single
electron ﬁeld at a dose of 21 Gy in three fractions, once per
day over three consecutive working days.
The radiotherapy target volume comprised the procedure
scar with a 3-cm margin inferiorly and laterally. The su-
perior margin corresponded to the superior border of three
ribs superior to the procedure scar. This approach maxi-
mized the chance of the whole procedure tract, from skin to
pleura, being covered by the treatment ﬁeld, which com-
monly runs over the rib superior to the site of insertion on
the chest wall. The electron energy was determined
TABLE 1. Baseline Characteristics
Characteristic
No RT
(n = 189) Prophylactic RT (n = 186)
Age (range), years 74.6 (49.2-90.4) 72.9 (52.3-89.8)
Sex
Male 167 (88.4) 167 (89.8)
Female 22 (11.6) 19 (10.2)
Procedure
VATS 97 (51.3) 108 (58.1)
Local anesthetic thoracoscopy 51 (27.0) 50 (26.9)
Intercostal chest drain 16 (8.5) 11 (5.9)
Open surgical biopsy 10 (5.3) 5 (2.7)
Other 15 (7.9) 12 (6.5)
ECOG PS score
0 45 (23.8) 60 (32.2)
1 106 (56.1) 105 (56.5)
2 38 (20.1) 21 (11.3)
Histology
Epithelioid 140 (74.1) 148 (79.6)
Other 49 (25.9) 38 (20.4)
Intention to administer chemotherapy
Yes 135 (71.4) 133 (71.5)
No 54 (28.6) 53 (28.5)
NOTE. Data reported as No. (%) unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, Performance Status; RT, radiotherapy; VATS, video-assisted thoracoscopic
surgery.
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according to local electron dose-depth calculations en-
suring greater than 90% of the prescribed dose was de-
livered to the pleura and to the skin surface, facilitated by
applying a 5-mm tissue-equivalent bolus to the whole
treatment ﬁeld, if required.
Chemotherapy was initiated at least 1 week after radio-
therapy for patients in the prophylactic radiotherapy group,
and after randomization for patients in the control group, at
the discretion of the treating clinician. Patients were fol-
lowed upmonthly for 24months or until the development of
CWM or death. Patients were reviewed in clinic at the time
of random assignment, and at 6, 12, 26, and 52 weeks after
randomization for an examination of the chest wall to assess
for visible and/or palpable signs of CWM and for toxicity
assessment, using Common Terminology Criteria for Ad-
verse Events, version 4.0. In addition, patients received
a monthly telephone follow-up with a research nurse to
determine if they had noted any chest wall nodules. If
a patient was suspicious that a nodule had developed, they
were invited to the clinic for assessment.
Patients were asked to complete a visual analog scale (VAS)
to score for pain (on a scale of 0 to 100 mm, with no pain at
0 mm and worst possible pain at 100 mm) at the time of
randomization, and at each telephone and clinic follow-up.
Patients were speciﬁcally asked to only consider pain at the
original site of the chest wall procedure or at the site of the
chest wall nodule, if present. Patients were removed from
the study only if they withdrew consent for ongoing trial
follow-up.
Outcomes
The primary end point was the incidence of metastases on
the ipsilateral chest wall 6 months (29 weeks to allow for
some variation in follow-up appointments) from randomi-
zation, within the intention-to-treat population. Incidence of
ipsilateral CWM was considered a clinically relevant and
reproducible primary end point not reliant on observer
interpretation of a virtual radiotherapy ﬁeld, which was
particularly important for patients in the no-radiotherapy
arm who did not have a radiotherapy ﬁeld planned at
baseline. The date of CWM was recorded as the date CWM
was conﬁrmed by the investigator in clinic. If the patient was
unable to attend the outpatient clinic, then the date of CWM
was recorded as the date of the telephone consultation
when the metastasis was reported.
Predeﬁned secondary outcomes were incidence of ipsi-
lateral CWM 12 months from randomization; time from
randomization to ipsilateral CWM; position of ipsilateral
CWM in relation to the radiotherapy ﬁeld in patients ran-
domly assigned to the prophylactic radiotherapy group (in
ﬁeld/out of ﬁeld); acute and late skin radiotherapy toxicity
(Common Terminology Criteria for Adverse Events, version
4.0); pain from ipsilateral CWM (VAS score).
Statistical Analysis
The sample size calculation was based on the published
literature,5-13 with the crude rate of CWM after a chest wall
procedure expected to be 15%, occurring 80% to 90% of
the time within 6 months of the chest wall procedure.
Comparing the proportion of patients in whom CWM de-
veloped by 6 months and the proportion of patients in
whom CWM did not develop or the proportion dying without
CWMwithin 6 months, it was considered that a reduction in
the incidence from 15% to 5% in favor of prophylactic
radiotherapy would be clinically signiﬁcant. On the basis of
a two-arm trial with a 5% signiﬁcance level, two-sided test,
and 80% power, 280 patients would be required. It was
anticipated that 25% of patients would not survive for
6months after random assignment; therefore, an additional
94 patients were required, for a total of 374 patients. The
study was powered to address the primary outcome only,
not the secondary end points. Before analysis, it was
recognized that it would be more appropriate to include
patients not surviving 6 months in the denominator rather
than excluding them, because the estimates from the
TABLE 2. Logistic Regression Analysis of Primary Outcome: Chest
Wall Metastases Within 6 months (29 weeks) From Randomization
Term OR 95% CI P
Trial arm* 0.598 0.212 to 1.684 .33
Conﬁrmed epithelioid histology† 0.949 0.296 to 3.039 .93
Intention to give chemotherapy† 1.204 0.378 to 3.834 .75
Constant 0.051 0.012 to 0.206 , .001
Abbreviation: OR, odds ratio.
*0 = No radiotherapy; 1 = prophylactic radiotherapy.
†0 = No; 1 = yes.
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FIG 2. Cumulative incidence of CWM in the prophylactic radio-
therapy group and the no radiotherapy group. CWM, chest wall
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binary analysis would then be more in line with those from
a competing risks analysis.
A Fisher’s exact test was used to compare the cumulative
incidence of CWM between the two arms at 6 months. A
logistic regression analysis was also conducted that ad-
justed for the two stratiﬁcation factors, histologic subtype,
and intention to give chemotherapy, used in the random-
ization algorithm.
Time from randomization to CWM was compared using
a Fine and Gray competing risks regression model ac-
counting for the competing risk of death without CWM.
Based on the hypothesis that CWM cause pain and result in
an increase in VAS pain score by at least 20 points, a VAS
pain score recorded after development of a metastasis was
compared with the baseline score and the differences
compared using a Wilcoxon matched-pairs test. Toxicity
and position of CWM in relation to the radiotherapy ﬁeld in
patients randomly assigned to the prophylactic radiother-
apy group were reported descriptively. The statistical
package used for the analyses was Stata, version 13.1; and
R. This study was registered with International Standard
Registered Clinical Trial Number (ISRCTN 04240319).
RESULTS
Between July 30, 2012, and December 12, 2015, 375
patients were recruited from 54 centers and randomly
assigned to receive prophylactic radiotherapy (n = 186) or
no prophylactic radiotherapy (n = 189; Fig 1). Baseline
characteristics of the two groups were well balanced
(Table 1), although there was a greater proportion of pa-
tients with Eastern Cooperative Oncology Group perfor-
mance status score of 2 in the no-radiotherapy group
(20.1%) compared with the prophylactic radiotherapy
group (11.3%). The proportion of patients receiving che-
motherapy was well balanced between the two groups
(66.7% in the prophylactic radiotherapy group compared
with 60.3% in the no-radiotherapy group). Median time
from randomization to ﬁrst cycle of chemotherapy was 25
(range, 6 to 210) days in the prophylactic radiotherapy
group compared with 17 (range, 2 to 400) days in the no-
radiotherapy group. In both groups, greater than 90% of
patients receiving chemotherapy were treated with
a pemetrexed and platinum doublet. Of the 186 partici-
pants allocated to the prophylactic radiotherapy group, 165
received a single radiotherapy ﬁeld delivering 21 Gy in three
fractions, and 16 participants had two chest wall procedure
sites treated, each receiving 21 Gy in three fractions.
At the time of analysis, the proportion of CWM 6 months
after randomization was 3.2% (six of 186 patients) versus
5.3% (10 of 189 patients) in the prophylactic radiotherapy
group and the no-radiotherapy group, respectively (odds
ratio [OR], 0.60; 95% CI, 0.17 to 1.86; P = .44). Of the 375
censored cases, 21 (5.3%) were included in the analysis of
proportions, but this did not markedly affect tests or esti-
mates (Fisher’s exact test, P = .44; x2 test, P = .32; and
a test using point estimates and variances from the cu-
mulative incidence curves, P = .29).
Logistic regression results adjusting for stratiﬁcation factors
for the primary analysis are listed in Table 2. The proportion
of CWM 12 months after randomization was 8.1% (15 of
186 patients) versus 10.1% (19 of 189 patients), re-
spectively (OR, 0.79; 95% CI, 0.36 to 1.69; P = .59).
There were 46 recorded CWM in total, 17 of 186 patients in
the prophylactic radiotherapy group and 29 of 189 patients
in the no-radiotherapy group. There was no signiﬁcant
difference in the cumulative incidence of CWM in the
prophylactic radiotherapy group versus the no-radiotherapy
group (subdistribution hazard ratio, 0.57; 95% CI, 0.31 to
1.03; P = .06), as shown in Figure 2. Similarly, there was no
signiﬁcant difference in cumulative incidence of CWM
when controlling for the stratiﬁcation factors (epithelioid
histology [no/yes] and intention to give chemotherapy [no/
yes]; Table 3).
In the prophylactic radiotherapy group, of the 17 partici-
pants in whom CWM developed, they developed within the
prophylactic radiotherapy ﬁeld in eight patients (47%),
outside of the prophylactic radiotherapy ﬁeld in seven
(41%), and data were not recorded for two patients.
Of the 46 patients in whom CWM developed, 38 had their
VAS pain score recorded at time of randomization and time
of event (Table 4). After CWM developed, pain was scored
as the same or better than baseline in 20 patients (52.6%)
and worse in 18 of the 38 patients (47.4%), with 12 re-
cording at least a 20-point increase in VAS pain score
(Wilcoxon matched-pairs test, P , .01).
Skin toxicity was the most common radiotherapy-related
adverse event in the 186 patients allocated to the pro-
phylactic radiotherapy group. Radiation dermatitis grade 1
was reported in 96 (51.6%), grade 2 in 19 (10.2%), and
TABLE 3. Fine and Gray Regression Model for the Cumulative Incidence of Chest
Wall Metastases With the Competing Risk of Death Without Preceding Chest Wall
Metastases
Term Subdistribution HR 95% CI P
Trial arm* 0.574 0.310 to 1.063 .08
Conﬁrmed epithelioid histology† 0.859 0.433 to 1.703 .66
Intention to give chemotherapy† 1.093 0.567 to 2.107 .79
Abbreviation: HR, hazard ratio.
*0 = No radiotherapy; 1 = prophylactic radiotherapy.
†0 = No; 1 = yes.
TABLE 4. Change in VAS Pain Score at Development of Chest Wall Metastases,
Compared With Baseline
Change in VAS Pain Score Radiotherapy No Radiotherapy Total (%)
No change/decrease 8 12 20 (52.6)
Increase 7 11 18 (47.4)
Abbreviation: VAS, Visual Analog Scale.
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grade 3 in 1 (0.5%) patient. One patient in the no-
radiotherapy group recorded a grade 2 radiation dermati-
tis. This patient was treated with palliative radiotherapy after
CWM developed. Radiation recall reaction was recorded
after chemotherapy for 13 patients in the prophylactic
radiotherapy group (10 [5.4%] grade 1, three [1.6%] grade
2). A rib fracture (grade 2) was recorded in one patient in
the prophylactic radiotherapy group. Other adverse events
of grade 3 or higher that were recorded were chest pain
(ﬁve of 186 patients [2.7%] in the prophylactic radiotherapy
group and two of 189 [1.1%] in the control group), and one
reported grade 3 skin induration in the no-radiotherapy
group (Table 5).
DISCUSSION
The results from this trial show that prophylactic radio-
therapy to the site of a diagnostic or therapeutic chest wall
procedure does not signiﬁcantly reduce the incidence of
subsequent CWM in patients diagnosed with MPM.
The incidence of CWM in the no-radiotherapy group was
less than anticipated. The predicted incidence of CWM in
the no-radiotherapy group of 15% at 6 months was based
on historical clinical trials and case-series data.5-13,16-18 The
overestimation could reﬂect the impact of chemotherapy
using pemetrexed and cisplatin or carboplatin, which has
been shown to improve survival in patients with MPM,26
and was planned at the time of randomization for greater
than 70% of participants. The statistics for our study were
based on previous clinical trials and case series conducted
before palliative chemotherapy for MPMwas an established
practice.
The results of this study are consistent with the ﬁndings
from the recently published Surgery for Mesothelioma After
Radiation Therapy (SMART) trial,27 a multicenter, phase III
trial in which 203 patients were randomly assigned (1:1) to
immediate radiotherapy to chest wall procedure sites or to
deferred radiotherapy. The differences in participants
recruited, radiotherapy technique, and end points between
our trial and the SMART trial are shown in Table 6. No
statistically signiﬁcant difference was identiﬁed in the in-
cidence of CWM at 12 months from randomization of the
immediate and deferred radiotherapy groups (nine of 102
patients [8.8%] v 16 of 101 (15.8%), respectively; OR,
0.51; 95% CI, 0.19 to 1.32; P = .14). Prophylactic radio-
therapy compared with deferred radiotherapy demon-
strated no signiﬁcant effect on quality of life, nor was there
any discernible decrease in health care costs.28 In contrast,
an earlier study by Boutin et al16 (N = 40 patients) dem-
onstrated a signiﬁcant reduction in the incidence of CWM in
the prophylactic radiotherapy arm. In that study, conducted
in the prechemotherapy era, the incidence of metastatic
nodules in the no-radiotherapy group was high (40%).
However, this hypothesis is not supported by two other
similar randomized clinical trials conducted before the era
of chemotherapy and that demonstrated a lower incidence
of CWM in the no-radiotherapy compared with the pro-
phylactic radiotherapy groups.17,18
The cumulative incidence analysis did not demonstrate
a signiﬁcant difference between the two groups in the time
to CWM development. The divergence in the curves seen
after 12 months from randomization illustrates that there
were an additional 10 CWM in the no-radiotherapy group
occurring later than 12 months after randomization,
compared with only two in the prophylactic radiotherapy
group. This difference in rate of CWM between the two
groups after 12 months from randomization was higher in
the group of participants with a histologic subtype known to
be associated with a better prognosis (epithelioid histology)
and for whom chemotherapy treatment was intended. This
was an exploratory analysis, and the trial was not powered
to detect a difference in the rate of CWM in these
TABLE 5. Toxicity
CTCAE Toxicity Grade
Adverse Event
Prophylactic RT (n = 186) No RT (n = 189)
1 2 3 1 2 3
Radiation dermatitis 96 (51.6) 19 (10.2) 1 (0.5) 0 1 (0.5) 0
Skin atrophy 6 (3.2) 0 0 1 (0.5) 0 0
Skin induration 13 (7.0) 1 (0.5) 0 7 (3.7) 0 1 (0.5)
Skin ulceration 2 (1.1) 0 0 0 0 0
Chest wall pain 37 (19.9) 17 (9.1) 5 (2.7) 31 (16.4) 13 (6.9) 2 (1.1)
Avascular necrosis 1 (0.5) 0 0 0 0 0
Rib fracture 0 1 (0.5) 0 0 0 0
Dermatologic radiation recall reaction 10 (5.4) 3 (1.6) 0 0 0 0
Pneumonitis 1 (0.5) 0 0 0 0 0
NOTE. Toxicity was graded according to CTCAE, version 4.0, maximum reported grade. Data reported as no. (%).
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; RT, radiotherapy.
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subgroups. It could be hypothesized that chemotherapy for
MPM delays the development of CWM after a diagnostic or
therapeutic procedure, resulting in a deferred beneﬁt from
prophylactic radiotherapy, particularly in patients with fa-
vorable histologic subtypes. This is consistent with ﬁndings
of the SMART trial, which demonstrated a longer median
time to development of CWM in patients with epithelioid
subtype compared with other tumor subtypes and in pa-
tients who received chemotherapy compared with no
chemotherapy.27
The current trial is larger than the four previous random-
ized, phase III clinical trials in this setting.16-18,26 By using
a variable radiotherapy ﬁeld margin, it is, to our knowledge,
the ﬁrst trial to adequately cover the entire portal tract and
account for the commonly used technique whereby the
pleura is accessed by passing a device over the superior
border of the adjacent rib to reduce the risk of injuring the
intercostal neurovascular bundle, which runs along the
inferior side of the rib.29 Contrary to a commonly held belief
that CWM are painful, this study demonstrated that more
than half of the CWM analyzed did not result in an increase
in VAS pain score.
This trial was limited by an absence of blinding of the
participants and investigators. In addition, it could be ar-
gued that this trial was underpowered to detect a more
modest reduction in the incidence of CWM after pro-
phylactic radiotherapy than was predicted, in the era of
palliative chemotherapy. However, the power of this study
was based on a hypothesis considered clinically relevant.
It is questionable whether a smaller beneﬁt, and thus
a larger number needed to treat, would be clinically
relevant in this group of patients with a 1-year survival rate
of less than 50%. Furthermore, the only previous ran-
domized trial to have demonstrated a beneﬁt from pro-
phylactic radiotherapy in this setting delivered the ﬁrst
fraction of treatment within 15 days of a chest wall
procedure, so the window of up to 42-days could explain
the conﬂicting results. However, the study was designed
to be pragmatic and translatable to the routine clinical
setting, where 42 days is achievable but few patients are
able to start treatment within 15 days of a diagnostic
procedure.
In conclusion, the results of this study do not support the
routine use of prophylactic radiotherapy after a diagnos-
tic or therapeutic chest wall procedure in the era of
TABLE 6. Comparison of PIT and SMART Trial Protocols
Characteristic PIT SMART
Sample size 374 203
Inclusion criteria
Open thoracotomy No Yes
Thoracoscopy Yes Yes
Large-bore chest tubes ($ 20 F) Yes Yes
Small-bore chest tubes (, 20 F) Yes No
Indwelling pleural catheters No Yes
Needle biopsy No No
RT ﬁeld size 3-cm Lateral/inferior borders; variable superior border 2 cm all directions
RT dose/fractionation 21 Gy in three fractions over 3 days 21 Gy in three fractions over 3 days
Primary end point Incidence of ipsilateral CWM at 6 months Incidence of CWM within 7 cm of the margins of the
procedure site at 12 months
Secondary end points Time to CWM Time to CWM
Pain from CWM Pain from CWM
Toxicity of treatment Toxicity of treatment
Locality of metastases to RT ﬁeld Quality of life
Incidence of CWM with indwelling catheters
Effect of chemotherapy
Semistructured qualitative interviews
Health economic analysis
Follow-up Clinic at 1, 3, 6, and 12 months;
monthly telephone follow-up
Clinic at 1, 3, 6, 9, and 12 months; monthly
telephone follow-up
Abbreviations: CWM, chest wall metastases; PIT, Prophylactic Irradiation of Tracts; RT, radiotherapy; SMART, Surgery for Mesothelioma After Radiation
Therapy.
1206 © 2019 by American Society of Clinical Oncology Volume 37, Issue 14
Bayman et al
Downloaded from ascopubs.org by 143.167.29.103 on September 2, 2019 from 143.167.029.103
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
chemotherapy for patients diagnosed with MPM. Our
ﬁndings conﬁrm that prophylactic radiotherapy should not
be considered part of the routine treatment of patients with
MPM who can be spared the limited but common skin
toxicity and the inconvenience of extra hospital visits
conferred by this unnecessary practice.
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